Navigation Links
Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Date:1/29/2008

(a development stage company)

Consolidated Statements of Operations

(Unaudited)

(In thousands, except share and per share amounts)

Period

from

February

4, 2002

inception

to

Three Months Twelve Months December

Ended December 31, Ended December 31, 31,

2006 2007 2006 2007 2007

Revenue:

Research revenue $- $1,375 $- $1,375 $1,375

Collaboration revenue - 409 - 409 409

Total revenue - 1,784 - 1,784 1,784

Operating Expenses:

Research and

development 14,186 9,670 33,630 31,074 89,878

General and

administrative 4,030 5,284 12,277 15,278 38,070

Impairment of

leasehold improvements - - - - 1,030

Depreciation and

amortization 291 313 952 1,237 2,794

In-process research

and development - - - - 418

Total operating

expenses 18,507 15,267 46,859 47,589 132,190

Loss from operations (18,507) (13,483) (46,859) (45,805) (130,406)

Other income (expenses):

Interest income 786 1,789 1,990 5,135 7,9
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
2. Amicus Therapeutics to Host R&D Day
3. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
4. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
5. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
6. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
7. Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
8. Cell Therapeutics, Inc. (CTI) Shareholders Authorize Share Increase at Special Meeting of Shareholders
9. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
10. Nile Therapeutics Appoints Gregory W. Schafer to Board of Directors
11. Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... PARIS and NEW YORK ... data from its open-label pilot study of mazindol in ... Design, Development and Therapy in December 2014 . ... of mazindol in children with attention deficit/hyperactivity disorder" ( ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) ...
(Date:12/22/2014)... GenomeDx Biosciences today announced that a new ... genomic test for prostate cancer, was able to predict ... radical prostatectomy without adjuvant therapy. Although rapid metastasis in ... tumor genomics to identify these men who have a ... advance. The study has been published online by ...
(Date:12/19/2014)... PA (PRWEB) December 19, 2014 ... leading developer and manufacturer of needle-free injection technology, ... agreement with Immunomic Therapeutics, Inc. (“ITI”) for ITI ... device with its LAMP™ vaccine platform. , ... an exclusive Worldwide license to the Biojector®-2000 that ...
(Date:12/19/2014)... CITY, Calif. , Dec. 19, 2014 Bina ... , USA) announced today that they have been acquired ... 1,2 is a privately held company that provides ... of next generation sequencing (NGS) data for the academic ... the Roche Sequencing Unit, and will continue to focus ...
Breaking Biology Technology:Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in ... for the treatment of Alzheimer,s and other neurological ... collaboration agreement with the University California, Irvine to ... vaccine candidate to induce an immune response against ...
... Conference: May 21-24, 2012 ,Exhibition: May 22-24, 2012 ,Pennsylvania ... Medical Design and Manufacturing (MD&M) East Conference have announced ... Convention Center, May 21 - 24, 2012. The conference ... dedicated to medical design and manufacturing professionals, featuring presentations ...
... CMC Biologics is a leading contract manufacturing organization (CMO) ... process development and cGMP manufacture of ... growth factors), as well as monoclonal antibodies. CMC ... characterization capabilities, expertise in continuous perfusion systems and ...
Cached Biology Technology:Intellect Neurosciences Enters Collaboration Agreement with Leading Alzheimer's Research Group at University of California Irvine to Test First in Class Dual Target Vaccine 2Intellect Neurosciences Enters Collaboration Agreement with Leading Alzheimer's Research Group at University of California Irvine to Test First in Class Dual Target Vaccine 3Intellect Neurosciences Enters Collaboration Agreement with Leading Alzheimer's Research Group at University of California Irvine to Test First in Class Dual Target Vaccine 4MD&M East 2012 to Feature FDA and Medical Technology Development Leaders 2CMC Biologics Highlights Technical Acumen at Upcoming Conferences 2CMC Biologics Highlights Technical Acumen at Upcoming Conferences 3CMC Biologics Highlights Technical Acumen at Upcoming Conferences 4CMC Biologics Highlights Technical Acumen at Upcoming Conferences 5
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... to their offering. One major ... technology. With continuous advances in technology, it is ... standard that meets the needs and expectations of ...
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader in ... seeing a staggering demand from its licensees for highly ... revealed, is not solely coming from fitness and health ... "A wearable is only as useful as ... is the ultimate driver in long-term mass consumer adoption ...
(Date:12/5/2014)... , Dec. 4, 2014 Increased emphasis ... investments in new testing and inspection technologies. The ... rise to a range of innovative test solutions. ... of Generation Y, which is generally more inclined ... result, product development strategies of test equipment vendors ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
... PITTSBURGH Nov. 9, 2007 Researchers at Childrens Hospital ... trial currently underway to study the effectiveness of oral insulin ... in people at risk for the disease. The researchers ... prevent or delay the onset of type 1 diabetes in ...
... will convene at the Institute of Ecosystem Studies ... future of biofuel production in the United States. ... biofuel experts, including Drs. David Pimentel (Cornell University), ... State)., Corn and soy-based ethanol have been touted ...
... barbecue knows that hot dogs are inexplicably packaged in different ... 10 hot dog buns. Put in ecological terms, this means ... are worthless without hot dogs to fill them. ... phosphorus or nitrogen limits plant production in most ecosystems. According ...
Cached Biology News:Children's Hospital studying drug with the potential to prevent/delay onset of type 1 diabetes 2Can plant-based ethanol save us from our fossil fuel addiction? 2At the root of nutrient limitation, ecosystems are not as different as they seem 2At the root of nutrient limitation, ecosystems are not as different as they seem 3
... new product number, created to easily match ... yet, please order under the old Sigma-Aldrich ... assistance. ID clarifier: tissue-culture treated ... cm 2 D H 245 ...
... Novagens PhageMaker System is optimized for maximum ... ligated with any bacteriophage l vector. Using a ... > 10^7 pfu/g arms (> 4 x 10^8 ... This one-tube system is extremely easy to use; ...
Mouse monoclonal [7B9] to beta II Tubulin ( Abpromise for all tested applications). Antigen: Synthetic peptide, CEEEEGEDEA found at the c-terminus of beta II tubulin. Entrez GeneID: 10383 ...
Polymerase (RNA) II (DNA directed) polypeptide L...
Biology Products: